Teva Gets What It Wants – Allergan Generics, Not Mylan
This article was originally published in The Tan Sheet
Executive Summary
Teva’s $40.5 billion acquisition of Allergan Generics will solidify Teva as the world’s leading generics company with $26 billion in combined revenues and 320 ANDAs pending at FDA.